References
ADHAM, N., KAO, H.T., SCHECTER, L.E., BARD, J., OLSEN, M., URQUHART, D., DURKIN, M., HARTIG, P.R., WEINSHANK, R.L. & BRANCHEK, T.A. (1993). Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A, 90, 408-12.
AGHAJANIAN, G.K. (1980). Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Brain Res, 186, 492-8.
AGHAJANIAN, G.K. & BING, O.H. (1964). Persistence of Lysergic Acid Diethylamide in the Plasma of Human Subjects. Clin Pharmacol Ther, 10, 611-4.
AGHAJANIAN, G.K., FOOTE, W.E. & SHEARD, M.H. (1970). Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Exp Ther, 171, 178-87.
AGHAJANIAN, G.K., FOOTE, W.E. & SHEARD, M.H. (1968). Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science, 161, 706-8.
AGHAJANIAN, G.K., HAIGLER, H.J. & BLOOM, F.E. (1972). Lysergic acid diethylamide and serotonin: direct actions on serotonin-containing neurons in rat brain. Life Sci I, 11, 615-22.
AGHAJANIAN, G.K. & HAILGLER, H.J. (1975). Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors. Psychopharmacol Commun, 1, 619-29.
AGHAJANIAN, G.K. & MAREK, G.J. (1998). Serotonin 5-HT2A receptors enhance asynchronous excitatory transmission in pyramidal cells (layer V) of prefrontal cortex. Soc Neurosci Abs, 24, 1366.
AGHAJANIAN, G.K. & MAREK, G.J. (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology, 36, 589-99.
AGHAJANIAN, G.K. & MAREK, G.J. (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res, 825, 161-71.
ANDEN, N.E., CORRODI, H. & FUXE, K. (1968). Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide or bufotenin. Br J Pharmacol, 34, 1-7.
ARVANOV, V.L., LIANG, X., MAGRO, P., ROBERTS, R. & WANG, R.Y. (1999a). A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci, 11, 2917-34.
ARVANOV, V.L., LIANG, X., RUSSO, A. & WANG, R.Y. (1999b). LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J Neurosci, 11, 3064-72.
BACON, S.J., HEADLAM, A.J., GABBOTT, P.L. & SMITH, A.D. (1996). Amygdala input to medial prefrontal cortex (mPFC) in the rat: a light and electron microscope study. Brain Res, 720, 211-9.
BARTHO, P., FREUND, T.F. & ACSADY, L. (2002). Selective GABAergic innervation of thalamic nuclei from zona incerta. Eur J Neurosci, 16, 999-1014.
BERENDSE, H.W. & GROENEWEGEN, H.J. (1991). Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience, 42, 73-102.
CERKETTI, A. & ROTHLIN, E. (1955). Role of 5-hydroxytryptamine in mental disease and its antagonism to lysergic acid derivatives. Nature, 176, 785-786.
CHIANG, C. & ASTON-JONES, G. (1993). A 5-hydroxytryptamine2 agonist augments gamma-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience, 54, 409-20.
CYR, M., LANDRY, M. & DI PAOLO, T. (2000). Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology, 23, 69-78.
DE MONTIGNY, C. & AGHAJANIAN, G.K. (1977). Preferential action of 5-methoxytryptamine and 5-methoxydimethyltryptamine on presynaptic serotonin receptors: A comparative iontophoretic study with LSD and serotonin. Neuropharmacology, 16, 811-818.
ENGEL, G., MULLER-SCHWEINITZER, E. & PALACIOS, J.M. (1984). 2-[125Iodo]LSD, a new ligand for the characterisation and localisation of 5-HT2 receptors. Naunyn Schmiedebergs Arch Pharmacol, 325, 328-36.
ERLANDER, M.G., LOVENBERG, T.W., BARON, B.M., DE LECEA, L., DANIELSON, P.E., RACKE, M., SLONE, A.L., SIEGEL, B.W., FOYE, P.E., CANNON, K. & ET AL. (1993). Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc Natl Acad Sci U S A, 90, 3452-6.
FIORELLA, D., RABIN, R.A. & WINTER, J.C. (1995). The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl), 121, 347-56.
GADDUM, J.H. (1953). Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J Physiol, 121, 15.
GADDUM, J.H. & HAMEED, K.A. (1954). Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol, 9, 240-248.
GERALD, C., ADHAM, N., KAO, H.T., OLSEN, M.A., LAZ, T.M., SCHECHTER, L.E., BARD, J.A., VAYSSE, P.J., HARTIG, P.R., BRANCHEK, T.A. & ET AL. (1995). The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. Embo J, 14, 2806-15.
GLENNON, R.A., TITELER, M. & MCKENNEY, J.D. (1984a). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci, 35, 2505-11.
GLENNON, R.A., TITELER, M. & YOUNG, R. (1986). Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol Bull, 22, 953-8.
GLENNON, R.A., YOUNG, R., HAUCK, A.E. & MCKENNEY, J.D. (1984b). Structure-activity studies on amphetamine analogs using drug discrimination methodology. Pharmacol Biochem Behav, 21, 895-901.
GLENNON, R.A., YOUNG, R. & ROSECRANS, J.A. (1983). Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol, 91, 189-96.
GOGERTY, J.H. & DILLE, J.M. (1957). Pharmacology of D-lysergic acid morpholide (LSM). J Pharmacol Exp Ther, 120, 340-348.
GOLSHANI, P. & JONES, E.G. (1999). Synchronized paroxysmal activity in the developing thalamocortical network mediated by corticothalamic projections and "silent" synapses. J Neurosci, 19, 2865-75.
GOUZOULIS-MAYFRANK, E., SCHRECKENBERGER, M., SABRI, O., ARNING, C., THELEN, B., SPITZER, M., KOVAR, K.A., HERMLE, L., BULL, U. & SASS, H. (1999). Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology, 20, 565-81.
GUILLERY, R.W. & HARTING, J.K. (2003). Structure and connections of the thalamic reticular nucleus: Advancing views over half a century. J Comp Neurol, 463, 360-71.
HAWKS, R.L. & CHIANG, C.N. (1986). Urine Testing for Drugs of Abuse. Rockville, MD: Department of Health and Human Services.
HOFFER, A. (1967). A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In The Use of LSD in Psychotherapy and Alcoholism. ed Abramson, H.A. pp. 343-406. Indianapolis: Bobbs-Merril.
HOYER, D. (1988). Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res, 8, 59-81.
JAKAB, R.L. & GOLDMAN-RAKIC, P.S. (1998). 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A, 95, 735-40.
JONES, E.G. (2002). Thalamic circuitry and thalamocortical synchrony. Philos Trans R Soc Lond B Biol Sci, 357, 1659-73.
JONES, H.E., LI, H. & BALSTER, R.L. (1998). Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav, 59, 413-8.
KIM, U. & MCCORMICK, D.A. (1998). The functional influence of burst and tonic firing mode on synaptic interactions in the thalamus. J Neurosci, 18, 9500-16.
KIRISCHUK, S. & GRANTYN, R. (2003). Intraterminal Ca2+ concentration and asynchronous transmitter release at single GABAergic boutons in rat collicular cultures. J Physiol, 548, 753-64.
KLODZINSKA, A., BIJAK, M., TOKARSKI, K. & PILC, A. (2002). Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav, 73, 327-32.
KURRASCH-ORBAUGH, D.M., PARRISH, J.C., WATTS, V.J. & NICHOLS, D.E. (2003). A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem, 86, 980-91.
LAMBE, E.K. & AGHAJANIAN, G.K. (2001). The role of Kv1.2-containing potassium channels in serotonin-induced glutamate release from thalamocortical terminals in rat frontal cortex. J Neurosci, 21, 9955-63.
LOVENBERG, T.W., BARON, B.M., DE LECEA, L., MILLER, J.D., PROSSER, R.A., REA, M.A., FOYE, P.E., RACKE, M., SLONE, A.L., SIEGEL, B.W. & ET AL. (1993a). A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron, 11, 449-58.
LOVENBERG, T.W., ERLANDER, M.G., BARON, B.M., RACKE, M., SLONE, A.L., SIEGEL, B.W., CRAFT, C.M., BURNS, J.E., DANIELSON, P.E. & SUTCLIFFE, J.G. (1993b). Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci U S A, 90, 2184-8.
MAREK, G.J. & AGHAJANIAN, G.K. (1999). 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol, 367, 197-206.
MAREK, G.J. & AGHAJANIAN, G.K. (1998). 5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation. Neuroscience, 86, 485-97.
MAREK, G.J. & AGHAJANIAN, G.K. (1996). LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther, 278, 1373-82.
MAREK, G.J., WRIGHT, R.A., GEWIRTZ, J.C. & SCHOEPP, D.D. (2001). A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience, 105, 379-92.
MAREK, G.J., WRIGHT, R.A., SCHOEPP, D.D., MONN, J.A. & AGHAJANIAN, G.K. (2000). Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther, 292, 76-87.
MARTIN-RUIZ, R., PUIG, M.V., CELADA, P., SHAPIRO, D.A., ROTH, B.L., MENGOD, G. & ARTIGAS, F. (2001). Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci, 21, 9856-66.
MATTHES, H., BOSCHERT, U., AMLAIKY, N., GRAILHE, R., PLASSAT, J.L., MUSCATELLI, F., MATTEI, M.G. & HEN, R. (1993). Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol, 43, 313-9.
MCCORMICK, D.A. & FEESER, H.R. (1990). Functional implications of burst firing and single spike activity in lateral geniculate relay neurons. Neuroscience, 39, 103-13.
MCKENNA, D.J. & SAAVEDRA, J.M. (1987). Autoradiography of LSD and 2,5-dimethoxyphenylisopropylamine psychotomimetics demonstrates regional, specific cross-displacement in the rat brain. Eur J Pharmacol, 142, 313-5.
MINER, L.A., BACKSTROM, J.R., SANDERS-BUSH, E. & SESACK, S.R. (2003). Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience, 116, 107-17.
MITCHELL, R., MCCULLOCH, D., LUTZ, E., JOHNSON, M., MACKENZIE, C., FENNELL, M., FINK, G., ZHOU, W. & SEALFON, S.C. (1998). Rhodopsin-family receptors associate with small G proteins to activate phospholipase D. Nature, 392, 411-4.
MITROFANIS, J. & MIKULETIC, L. (1999). Organisation of the cortical projection to the zona incerta of the thalamus. J Comp Neurol, 412, 173-85.
MONSMA, F.J., JR., SHEN, Y., WARD, R.P., HAMBLIN, M.W. & SIBLEY, D.R. (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol, 43, 320-7.
MORENO, H., KENTROS, C., BUENO, E., WEISER, M., HERNANDEZ, A., VEGA-SAENZ DE MIERA, E., PONCE, A., THORNHILL, W. & RUDY, B. (1995). Thalamocortical projections have a K+ channel that is phosphorylated and modulated by cAMP-dependent protein kinase. J Neurosci, 15, 5486-501.
NELSON, D.L., LUCAITES, V.L., WAINSCOTT, D.B. & GLENNON, R.A. (1999). Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol, 359, 1-6.
NICHOLS, D.E. (2004). Hallucinogens. Pharmacol Ther, 101, 131-81.
PALACIOS, J.M., HOYER, D. & CORTES, R. (1987). alpha 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates. Brain Res, 419, 65-75.
PEROUTKA, S.J. & HAMIK, A. (1988). [3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes. Eur J Pharmacol, 148, 297-9.
PIERCE, P.A. & PEROUTKA, S.J. (1989). Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl), 97, 118-22.
POLING, J.S., KARANIAN, J.W., SALEM, N., JR. & VICINI, S. (1995). Time- and voltage-dependent block of delayed rectifier potassium channels by docosahexaenoic acid. Mol Pharmacol, 47, 381-90.
POLING, J.S., ROGAWSKI, M.A., SALEM, N., JR. & VICINI, S. (1996). Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. Neuropharmacology, 35, 983-91.
POMPEIANO, M., PALACIOS, J.M. & MENGOD, G. (1994). Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res, 23, 163-78.
PORTER, R.H., BENWELL, K.R., LAMB, H., MALCOLM, C.S., ALLEN, N.H., REVELL, D.F., ADAMS, D.R. & SHEARDOWN, M.J. (1999). Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol, 128, 13-20.
PUIG, M.V., CELADA, P., DIAZ-MATAIX, L. & ARTIGAS, F. (2003). In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex, 13, 870-82.
RASMUSSEN, K. & AGHAJANIAN, G.K. (1986). Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists. Brain Res, 385, 395-400.
RASMUSSEN, K., GLENNON, R.A. & AGHAJANIAN, G.K. (1986). Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity. Eur J Pharmacol, 132, 79-82.
ROBERTSON, D.N., JOHNSON, M.S., MOGGACH, L.O., HOLLAND, P.J., LUTZ, E.M. & MITCHELL, R. (2003). Selective interaction of ARF1 with the carboxy-terminal tail domain of the 5-HT2A receptor. Mol Pharmacol, 64, 1239-50.
ROGAWSKI, M.A. & AGHAJANIAN, G.K. (1979). Response of central monoaminergic neurons to lisuride: comparison with LSD. Life Sci, 24, 1289-97.
RUAT, M., TRAIFFORT, E., LEURS, R., TARDIVEL-LACOMBE, J., DIAZ, J., ARRANG, J.M. & SCHWARTZ, J.C. (1993). Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci U S A, 90, 8547-51.
RUCK, C.A., BIGWOOD, J., STAPLES, D., OTT, J. & WASSON, R.G. (1979). Entheogens. J Psychedelic Drugs, 11, 145-146.
RUMPEL, E. & BEHRENDS, J.C. (1999). Sr2+-dependent asynchronous evoked transmission at rat striatal inhibitory synapses in vitro. J Physiol, 514 ( Pt 2), 447-58.
SANCHEZ-VIVES, M.V. & MCCORMICK, D.A. (2000). Cellular and network mechanisms of rhythmic recurrent activity in neocortex. Nat Neurosci, 3, 1027-34.
SANDERS-BUSH, E., BURRIS, K.D. & KNOTH, K. (1988). Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther, 246, 924-8.
SARA, S.J., VANKOV, A. & HERVE, A. (1994). Locus coeruleus-evoked responses in behaving rats: a clue to the role of noradrenaline in memory. Brain Res Bull, 35, 457-65.
SCHMUCK, K., ULLMER, C., ENGELS, P. & LUBBERT, H. (1994). Cloning and functional characterization of the human 5-HT2B serotonin receptor. FEBS Lett, 342, 85-90.
SCHREIBER, R., BROCCO, M. & MILLAN, M.J. (1994). Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol, 264, 99-102.
SCRUGGS, J.L., SCHMIDT, D. & DEUTCH, A.Y. (2003). The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci Lett, 346, 137-40.
SHULGIN, A.T. & SHULGIN, A. (1991). PiHKAL: A Chemical Love Story. Berkeley, CA: Transform Press.
SHULGIN, A.T. & SHULGIN, A. (1997). TiHKAL: The Continuation. Berkeley, CA: Transform Press.
SMITH, R.L., CANTON, H., BARRETT, R.J. & SANDERS-BUSH, E. (1998). Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol Biochem Behav, 61, 323-30.
STERIADE, M. & AMZICA, F. (1996). Intracortical and corticothalamic coherency of fast spontaneous oscillations. Proc Natl Acad Sci U S A, 93, 2533-8.
STRASSMAN, R.J. (1996). Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res, 73, 121-4.
TITELER, M., LYON, R.A. & GLENNON, R.A. (1988). Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl), 94, 213-6.
TRULSON, M.E., HEYM, J. & JACOBS, B.L. (1981). Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats. Brain Res, 215, 275-93.
TWAROG, B.M. & PAGE, I.H. (1953). Am J Physiol, 175, 157.
VILLALOBOS, C.A., BULL, P., SAEZ, P., CASSELS, B.K. & HUIDOBRO-TORO, J.P. (2004). 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br J Pharmacol, 141, 1167-74.
VOLLENWEIDER, F.X. (2001). Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci, 3, 265-279.
VOLLENWEIDER, F.X. & GEYER, M.A. (2001). A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull, 56, 495-507.
VOLLENWEIDER, F.X., VOLLENWEIDER-SCHERPENHUYZEN, M.F., BABLER, A., VOGEL, H. & HELL, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport, 9, 3897-902.
VOTAVA, Z., PODVALOVA, I. & SEMONSKY, M. (1958). Studies on the pharmacology of D-lysergic acid cycloalklamdes. Arch Int Pharmacodyn Ther, 115, 114-130.
WEISER, M., VEGA-SAENZ DE MIERA, E., KENTROS, C., MORENO, H., FRANZEN, L., HILLMAN, D., BAKER, H. & RUDY, B. (1994). Differential expression of Shaw-related K+ channels in the rat central nervous system. J Neurosci, 14, 949-72.
WEST, W.B., LOU, A., PECHERSKY, K., CHACHICH, M.E. & APPEL, J.B. (2000). Antagonism of a PCP drug discrimination by hallucinogens and related drugs. Neuropsychopharmacology, 22, 618-25.
WINTER, J.C., ECKLER, J.R. & RABIN, R.A. (2004). Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (Berl), 172, 233-40.
WONG, D.F., LEVER, J.R., HARTIG, P.R., DANNALS, R.F., VILLEMAGNE, V., HOFFMAN, B.J., WILSON, A.A., RAVERT, H.T., LINKS, J.M., SCHEFFEL, U. & ET AL. (1987). Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using N1-([11C]-methyl)-2-Br-LSD. Synapse, 1, 393-8.
WOODWARD, D.J., MOISES, H.C., WATERHOUSE, B.D., YEH, H.H. & CHEUN, J.E. (1991). The cerebellar norepinephrine system: inhibition, modulation, and gating. Prog Brain Res, 88, 331-41.
WOOLLEY, D.W. & SHAW, E. (1954). A biochemical and pharmacological suggestion about certain mental disorders. Science, 199, 587-588.
WRIGHT, D.E., SEROOGY, K.B., LUNDGREN, K.H., DAVIS, B.M. & JENNES, L. (1995). Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol, 351, 357-73.
ZGOMBICK, J.M., SCHECHTER, L.E., MACCHI, M., HARTIG, P.R., BRANCHEK, T.A. & WEINSHANK, R.L. (1992). Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor. Mol Pharmacol, 42, 180-5.